Reviewing RedHill Biopharma Ltd. (RDHL)’s and Its Peers results

RedHill Biopharma Ltd. (NASDAQ:RDHL) is a company in the Biotechnology industry and that’s how we contrast it to its rivals. The contrasting will be based on the profitability, analyst recommendations, risk, institutional ownership, dividends, earnings and valuation.

Institutional & Insider Ownership

26.06% of RedHill Biopharma Ltd.’s shares are held by institutional investors. Comparatively, 50.88% of all Biotechnology’s companies shares are held by institutional investors. 5.84% of RedHill Biopharma Ltd. shares are held by company insiders. Comparatively, 8.18% of all Biotechnology companies shares are held by company insiders.


Table 1 has RedHill Biopharma Ltd. and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
RedHill Biopharma Ltd. -461.67% 0.00% 0.00%
Industry Average 1,464.25% 88.44% 21.62%

Earnings & Valuation

In next table we are contrasting RedHill Biopharma Ltd. and its rivals’ net profit, valuation and top-line revenue.

Net Income Gross Revenue Price/Earnings Ratio
RedHill Biopharma Ltd. 41.55M 9.00M 0.00
Industry Average 34.08M 2.33M 58.78

Analyst Recommendations

Table 3 shows summary of recent ratings for RedHill Biopharma Ltd. and its rivals.

Sell Ratings Hold Ratings Buy Ratings Rating Score
RedHill Biopharma Ltd. 0 0 0 0.00
Industry Average 1.17 1.78 2.01 2.68

As a group, Biotechnology companies have a potential upside of 173.20%.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of RedHill Biopharma Ltd. and its peers.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
RedHill Biopharma Ltd. -17% -15.9% -5.55% -3.99% 41.01% 35.8%
Industry Average 9.08% 15.16% 32.92% 41.89% 74.81% 65.27%

For the past year RedHill Biopharma Ltd. has weaker performance than RedHill Biopharma Ltd.’s rivals.


RedHill Biopharma Ltd. does not pay a dividend.


RedHill Biopharma Ltd.’s rivals beat RedHill Biopharma Ltd. on 4 of the 4 factors.

RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for the treatment of gastrointestinal and inflammatory diseases, and cancer. The company promotes two gastrointestinal products in the U.S., such as Donnatal, a prescription oral adjunctive drug used in the treatment of IBS and acute enterocolitis; and EnteraGam, a medical food intended for the dietary management under medical supervision of chronic diarrhea and loose stools. Its clinical-stage pipeline includes TALICIA (RHB-105), an oral combination therapy for the treatment of Helicobacter pylori infection with successful results from a first Phase III study and an ongoing confirmatory Phase III study; RHB-104, an oral combination therapy for the treatment of Crohn's disease with an ongoing first Phase III study, a completed proof-of-concept Phase IIa study for multiple sclerosis, and QIDP status for nontuberculous mycobacteria infections; BEKINDA (RHB-102), a once-daily oral pill formulation of ondansetron with successful top-line results in a Phase III study for acute gastroenteritis and gastritis and an ongoing Phase II study for IBS-D; RHB-106, an encapsulated bowel preparation licensed to Salix Pharmaceuticals, Ltd.; YELIVA (ABC294640), a Phase II-stage, orally-administered, first-in-class SK2 selective inhibitor targeting multiple oncology, inflammatory, and gastrointestinal indications; MESUPRON, a Phase II-stage first-in-class, orally-administered protease inhibitor, targeting pancreatic cancer and other solid tumors; and RIZAPORT (RHB-103), an oral thin film formulation of rizatriptan for acute migraines, with a U.S. NDA currently under discussion with the FDA and marketing authorization received in two European Union member states under the European Decentralized Procedure. The company was founded in 2009 and is headquartered in Tel Aviv, Israel.